Trial
NCT04277936
Pharmacologic Modulation of Hippocampal Activity in Psychosis
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Vanderbilt University Medical Center
Collaborators
—
Condition
Schizophrenia
Intervention
Levetiracetam 500 mg
Why stopped
Study was redesigned and submitted as a new protocol (NCT04559529).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-05